Kirkland & Ellis Represents Bristol Myers in iPierian Acquisition

Kirkland & Ellis LLP represents Bristol-Myers Squibb Company (NYSE: BMY) in its acquisition announced today of iPierian, Inc., a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain. Under the terms of the agreement, BMS has acquired all of iPierian’s issued and outstanding shares of capital stock and all common stock equivalents in an all cash transaction for a purchase price of $175 million, with the potential for additional development and regulatory milestone payments totaling $550 million, along with future royalties on net sales.

The Kirkland team includes corporate partners Daniel Wolf and David Feirstein in New York.